Expert Review of Pharmacoeconomics and Outcomes Research

Pharmacoeconomic studies and the pharmaceutical industry: bias in which direction?
pp. 665-667(3)
Author: Halpern, Michael

News in Brief
pp. 669-672(4)

Pharmacoeconomic aspects of memantine (Ebixa®) in the treatment of Alzheimer’s disease
pp. 675-680(6)
Author: Wimo, Anders

Self-management programs in chronic obstructive pulmonary disease: are they worthy?
pp. 681-683(3)
Author: Antoniu, Sabina A

Usefulness of resource utilization estimates from piggyback studies in rheumatoid arthritis
pp. 685-689(5)
Authors: Evans, Christopher; Crawford, Bruce; Doyle, Joseph

Impact of socioeconomic status on cardiovascular outcomes in Canada
pp. 691-702(12)
Authors: Alter, David A; Brandes, Shana; Irvine, Jane; Iron, Karey

Measurement strategies for indirect costs in economic evaluations
pp. 703-716(14)
Authors: Evans, Christopher; Mertzanis, Polyxane; Abetz, Linda

Methodological issues in the monetary valuation of benefits in healthcare
pp. 717-727(11)
Authors: Ryan, Mandy; Watson, Verity; Amaya-Amaya, Mabelle

Economic considerations and future directions for lung volume reduction surgery
pp. 729-740(12)
Authors: Reed, Anna; Williams, Trevor; Snell, Gregory

Cost-effectiveness of Advair®: fluticasone propionate and salmeterol combination
pp. 741-747(7)
Authors: Tano, Benoit; Pathak, Dev; Hoffmann, Stephen

Cost-effectiveness of community-acquired pneumonia therapy
pp. 749-756(8)
Authors: Foley, Raymond J; Metersky, Mark L

Potential cost-effectiveness of colorectal cancer chemoprevention with nonsteroidal anti-inflammatory drugs
pp. 757-771(15)
Author: Ladabaum, Uri

Economic evaluation of aromatase inhibitors for the treatment of breast cancer
pp. 773-781(9)
Authors: Alousi, Amin M; Stano, Miron; Simon, Michael S

Item response theory and health-related quality of life in cancer
pp. 783-791(9)
Authors: Gershon, Richard; Cella, David; Dineen, Kelly; Rosenbloom, Sarah; Peterman, Amy; Lai, Jin-Shei